{"filings":[{"id":1397798,"accession_number":"0001493152-26-031668","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-07-02T12:40:16+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cingulate joins Russell 3000E Index; CMO trial period extended to Sept 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added to Russell 3000E Index, effective after June 2026 reconstitution; semi-annual reconstitution begins Dec 2026.","CEO Shane Schaffer says inclusion enhances visibility with institutional investors and supports long-term growth.","Employment agreement amendment extends CMO Matthew N. Brams' trial period from June 30 to September 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066316,"accession_number":"0001493152-26-028815","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-06-16T12:10:17+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.","First company-owned US patent for lead ADHD asset; includes composition-of-matter and method-of-treatment claims.","Cingulate holds additional patents in 30 European territories, Australia, Canada, Israel; applications pending in Hong Kong and South Korea.","CTx-1301 is a once-daily trimodal tablet using Precision Timed Release platform; being developed under FDA 505(b)(2) pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787996,"accession_number":"0001493152-26-026760","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-06-02T12:10:25+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued a Complete Response Letter for CTx-1301 (dexmethylphenidate HCl) NDA for ADHD.","No current concerns about clinical safety or efficacy; CMC information requests identified.","Company expects prompt resubmission of requested CMC data; has ~$30M cash on hand.","NDA previously accepted with PDUFA target date of May 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":528476,"accession_number":"0001493152-26-024435","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-05-19T20:50:25+00:00","items":["5.02"],"status":"ready","headline":"Cingulate board reduces size; two directors not seeking re-election; Hargroves changes class","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at 2026 Annual Meeting.","Board intends to reduce size to five directors and appoint a new chairman.","Jeff Hargroves resigned as Class I director and was reappointed as Class II director to maintain class balance.","Following reappointment, Class I directors are Peter Werth and Frederick Jiang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78002,"accession_number":"0001493152-26-022881","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-05-14T12:10:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.","Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.","FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.","Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.","R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96364,"accession_number":"0001493152-26-014914","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate appoints Frederick Jiang to Board; grants 15,000-share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zhanpeng 'Frederick' Jiang appointed Class I director effective March 27, 2026.","He will serve on Audit, Compensation, and Nominating Committees; deemed independent.","Granted option to purchase 15,000 shares vesting over 1 year in two installments.","Annual cash retainers: $40,000 for Board plus $7,500 Audit, $5,000 Compensation, $4,000 Nominating.","Appointment follows stockholder approval of a prior securities purchase agreement (Jan 28, 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110216,"accession_number":"0001493152-26-012417","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","5.07"],"status":"ready","headline":"Cingulate enters $100M at-the-market equity facility with A.G.P.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with A.G.P./Alliance Global Partners for up to $100M gross proceeds.","Company may sell shares at-the-market on Nasdaq; A.G.P. receives 3.0% commission.","Stockholders approved issuance of common stock upon conversion of Series A Preferred and warrant exercise.","Special Meeting approval clears Nasdaq Listing Rule 5635(b) requirement for prior issuance.","Adjournment proposal also passed but not needed as sufficient votes obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110215,"accession_number":"0001493152-26-010881","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.","Cash $11.0M at Dec 31, 2025; expects runway into late Q4 2026.","USPTO Notice of Allowance for CTx-1301 patent; protection through May 2042.","NDA for CTx-1301 accepted under 505(b)(2); PDUFA target date May 31, 2026.","Closed $12M at-the-market PIPE in Feb 2026 led by Falcon Creek Capital; 180-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110214,"accession_number":"0001493152-26-006942","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage","Jeff Hargroves appointed as Class I director and to Audit, Compensation, and Nominating committees","Company issued 25,786 shares at $6.16 per share to a lender in exchange for debt under Section 3(a)(9)","All PIPE investors subject to 180-day lock-up; total potential proceeds up to $21.4 million","FDA PDUFA target date for CTx-1301 ADHD treatment set for May 31, 2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110213,"accession_number":"0001493152-26-005561","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Cingulate closes $6.5M private placement tranche; issues shares for debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed portion of private placement for gross proceeds of $6.5M on Feb 6, 2026; remaining $5.5M expected to close soon.","Issued 361,409 shares to a lender from Jan 6 to Feb 5, 2026, in exchange for debt, at prices from $4.35 to $6.01 per share.","All issuances were exempt from registration under Section 3(a)(9) of the Securities Act.","Private placement was previously announced in Form 8-K dated January 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110212,"accession_number":"0001493152-26-004030","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Cingulate raises ~$12M in private placement of common stock, preferred, and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$12M; issues 2.15M common shares, 973 shares Series A preferred at $1,000 stated value, and warrants for 1.87M shares.","Purchase price $5.14 per common share (includes $0.10 per warrant share); conversion/exercise price $5.04.","Series A preferred carries 12% cumulative annual dividend; conversion requires stockholder approval.","Falcon Creek (manager of lead investor) may designate two directors after stockholder approval.","Proceeds used for working capital and general corporate purposes; 180-day lock-up and 24-month standstill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110211,"accession_number":"0001493152-26-002417","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cingulate ups ATM offering by $8.4M to $31.94M, files new prospectus supplement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price increased from $23,536,658 to $31,936,658 under ATM with H.C. Wainwright.","New prospectus supplement covers $8,840,000 of common stock issuable under the Sales Agreement.","Prior to Jan 12, 2026, the company had sold $15,145,503.74 of common stock under the ATM.","Legal opinion from Lowenstein Sandler LLP on the newly registered shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110210,"accession_number":"0001493152-26-000142","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 426,853 shares to lenders through debt conversion from Nov 21 to Jan 2","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued shares in six tranches between Nov 21, 2025 and Jan 2, 2026 to settle debt.","Share prices ranged from $3.39 to $4.13 per share; total ~$1.65M of debt exchanged.","All issuances exempt from registration under Section 3(a)(9) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126770,"accession_number":"0001493152-25-027667","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Shane Schaffer reinstated after no-contest plea; amended employment agreement modified severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shane Schaffer reinstated as CEO Dec 15, 2025, after administrative leave; pled no contest to misdemeanor, received 12 months probation.","Amended employment agreement: base salary reinstated; 'Cause' definition expanded to include probation violation; board vote reduced to majority.","Severance modified: lump sum lowered to 1x base+bonus (without cause/good reason) and 1.5x base+bonus (change in control).","John Roberts ends Executive Chairman role but remains Chairman; Jennifer Callahan continues as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126769,"accession_number":"0001493152-25-022132","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).","Cash $6.1M at Sep 30, 2025; company says it needs ~$7M additional capital to fund through May 2026 PDUFA.","FDA accepted NDA for ADHD drug CTx-1301; PDUFA target date May 31, 2026; $4.3M fee waiver granted.","Appointed Bryan Downey as CCO; closed $6M promissory note financing with 9% interest, maturing 18 months.","Commercial supply agreement with Bend Bio Sciences for exclusive U.S. manufacture of CTx-1301 through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126768,"accession_number":"0001493152-25-021410","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Cingulate completes $6M debt financing, appoints Bryan Downey as CCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.","Bryan Downey appointed Chief Commercial Officer; granted 30,000 options at $3.80/share, vesting over 4 years.","Cash runway extended into Q2 2026; proceeds for working capital and general corporate purposes.","FDA accepted NDA for CTx-1301 (ADHD); PDUFA target action date May 31, 2026.","Note includes monthly redemption up to $660k after PDUFA; company can defer up to 2 redemptions with 1% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126767,"accession_number":"0001493152-25-017931","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts Cingulate's NDA for CTx-1301 in ADHD; PDUFA date May 31, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for CTx-1301 (dexmethylphenidate), a once-daily PTR stimulant for ADHD in children and adults, under 505(b)(2) pathway.","PDUFA target action date is May 31, 2026; acceptance confirms submission sufficiently complete for substantive review.","Phase 3 trials showed large effect sizes on PERMP, AISRS, ADHD-RS-5, CGI scales; no serious treatment-emergent adverse events.","Commercial readiness: process transfer and scale-up completed with Bend Bio Sciences; AI-driven omnichannel platform with Indegene launched.","Early payer research indicates strong formulary receptivity for once-daily CTx-1301, aligning with adherence priorities in ADHD care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143561,"accession_number":"0001493152-25-014963","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cingulate shareholders approve issuance of >20% stock to Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of >20% of common stock to Lincoln Park Capital Fund, LLC under purchase agreement.","Vote results: 1,597,394 For, 213,885 Against, 9,561 Abstain; no broker non-votes.","Adjournment proposal approved but not needed due to sufficient votes for the Issuance Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143560,"accession_number":"0001493152-25-012753","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 325,729 shares to lenders in debt-for-equity swaps","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["July 30: 58,139 shares at $5.16 per share issued to lender for debt reduction.","August 12: 74,074 shares at $4.05 per share issued to lender.","August 21: 64,102 shares at $3.90 per share issued to lender.","August 29: 63,451 shares at $3.94 per share; Sept 5: 65,963 at $3.79 per share.","All issuances exempt under Section 3(a)(9) of Securities Act as exchanges with existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143559,"accession_number":"0001493152-25-012449","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate sets exec chairman retainer at $10K/mo; CEO on leave at 75% pay; ex-exec Myers gets $436K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John A. Roberts appointed Executive Chairman effective Aug 14; receives $10,000/month cash retainer.","CEO Shane Schaffer on administrative leave; salary reduced to 75% with benefits continued.","Laurie Myers employment ended Aug 7; Separation Agreement signed Aug 28 for $436,720 severance paid over 12 months.","Myers' unvested stock options fully vest and remain exercisable; post-employment restrictions including non-disparagement apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143558,"accession_number":"0001641172-25-024741","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q2 net loss widens to $4.8M; files NDA for CTx-1301 with FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.8M in Q2 2025, up from $3.2M in Q2 2024; R&D spend +43.6% to $2.7M.","Cash and cash equivalents $8.9M as of June 30, 2025; expects cash needs into late 2025; needs ~$1.5M more for commercialization.","Submitted NDA to FDA for lead asset CTx-1301 (dexmethylphenidate) on July 31, 2025; FDA decision on acceptance expected in 60 days.","Executed $25M purchase agreement with Lincoln Park Capital for at-the-market common stock sales over 36 months.","Phase 3 pediatric study showed marked improvement in ADHD symptoms at week five."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143557,"accession_number":"0001641172-25-024286","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate CEO Shane Schaffer charged with aggravated domestic battery; placed on administrative leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Shane Schaffer charged with one count of aggravated domestic battery on August 9, 2025.","Board placed Dr. Schaffer on administrative leave on August 14, 2025, pending legal resolution.","CFO Jennifer Callahan appointed interim CEO, continuing as CFO until further Board action.","Director John A. Roberts appointed Executive Chairman to provide operational support to management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143556,"accession_number":"0001641172-25-022664","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate terminates EVP/COO Laurie A. Myers on August 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laurie A. Myers, Executive Vice President and Chief Operating Officer, terminated.","Effective date of termination: August 7, 2025.","No successor or interim replacement announced; no reason provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143555,"accession_number":"0001641172-25-022360","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cingulate submits NDA to FDA for lead ADHD drug CTx-1301","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.","FDA will decide on acceptance within 60 days of July 31 submission.","Drug designed as novel extended-release tablet for once-daily, entire active-day symptom control.","Cingulate targets $23B U.S. ADHD market; over 20M patients diagnosed in US.","NDA is first regulatory application of company's proprietary Precision Timed Release platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143554,"accession_number":"0001641172-25-021006","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 144,063 common shares and 30,000 option in unregistered sales from Mar 31 to Jul 21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,538 shares at $4.36/share to a service provider on May 12, 2025.","Issued 73,068 shares at $4.79/share to a lender for debt reduction on July 21, 2025; additional debt exchanges of 5,986 and 57,471 shares on July 10 and 14 at $4.18 and $4.35/share.","Granted officer option to buy 30,000 shares at $4.51, vesting over 4 years with 25% after one year.","All issuances exempt under Securities Act Sections 4(a)(2) or 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143553,"accession_number":"0001641172-25-020618","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cingulate enters $25M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lincoln Park Capital commits to buy up to $25M of Cingulate common stock over 36 months, starting after SEC registration effective.","Cingulate issued 120,424 commitment shares to Lincoln Park on July 21, 2025 as consideration for the commitment.","Sales are at Cingulate's discretion with a single-day cap of $150K (up to $500K depending on price) and an Exchange Cap of 1,004,660 shares (19.99% of outstanding).","Proceeds intended for regulatory approval and development of CTx-1301, plus working capital and R&D.","Lincoln Park is barred from short sales or hedging during the term; Cingulate may terminate with one business day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161750,"accession_number":"0001641172-25-014621","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cingulate stockholders approve reverse stock split (1:2 to 1:25) and equity plan share increase to 1,141,826","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized a reverse stock split at a ratio between 1:2 and 1:25, to be determined by board before June 10, 2026.","Equity plan shares increased by 800,000 to 1,141,826, approved by 606,730 votes for vs 165,846 against.","Peter J. Werth elected as Class I director for term ending 2028, with 732,644 votes for.","KPMG LLP ratified as independent auditor for 2025, with 2,434,032 votes for.","Adjournment proposal deemed unnecessary; all proposals passed with sufficient votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161749,"accession_number":"0001641172-25-009989","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Cingulate terminates grant agreement for CTx-2103; no funds received","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Grant Agreement with private family foundation on May 13, 2025, originally signed April 8, 2025.","No grant funds were received; no repayment or refund obligation to the foundation.","All prospective royalty and other commercialization obligations for CTx-2103 have been terminated.","Company expects to continue CTx-2103 development in 3Q 2026 after potential launch of lead asset CTx-1301."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161748,"accession_number":"0001641172-25-009286","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.","Cash and equivalents $9.5M at March 31, 2025; cash runway into Q4 2025 beyond NDA submission.","Pre-NDA meeting with FDA completed April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.","Received $3M non-dilutive grant from private foundation to accelerate CTx-2103 (buspirone) anxiety asset.","Working capital $4.9M at Q1 end, down from $7.7M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161747,"accession_number":"0001641172-25-003329","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.","Non-dilutive funding; contingent royalty of $500K per quarter after first commercial sale, max cumulative $3.5M.","CTx-2103 (buspirone) potential first once-daily formulation for anxiety; U.S. market $5.5B, global $11.6B.","Grant expands pipeline and validates Cingulate's proprietary Precision Timed Release drug delivery platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179842,"accession_number":"0001641172-25-000689","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate reports FY 2024 net loss $15.5M; cash runway extended to Q4 2025, NDA for CTx-1301 targeted mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $12.2M (vs $52k Dec 2023); working capital improved to $7.5M from -$9.6M.","Net loss narrowed to $15.5M from $23.5M in 2023; R&D expenses fell to $9.4M from $15.5M.","Pre-NDA FDA meeting scheduled April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.","Phase 3 pediatric safety data showed no serious TEAEs across nine clinical trials.","Raised $17.5M in capital in 2024 via public offering, warrant inducement, and promissory note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179841,"accession_number":"0001493152-25-008988","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cingulate reports Phase 3 safety data for ADHD drug CTx-1301; no serious adverse events in final trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No serious treatment-emergent adverse events, deaths, or clinically relevant trends in two pediatric Phase 3 studies and one food-effect study.","Food-effect study with 50mg dose shows CTx-1301 can be taken with or without food, consistent with prior 25mg study.","Final combined adult and pediatric safety and efficacy analysis expected mid-2025 for NDA submission.","Pre-NDA in-person meeting with FDA scheduled for April 2, 2025.","Company had 3,647,655 shares of common stock outstanding as of March 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179840,"accession_number":"0001493152-25-004697","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cingulate announces dismissal of charge against CEO Shane Schaffer","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Charge against CEO Shane Schaffer dismissed on January 28, 2025; matter resolved.","Single allegation previously disclosed on October 4, 2024; no further details provided.","Board expresses full confidence and support for Dr. Schaffer to lead the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179839,"accession_number":"0001493152-25-003619","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cingulate amends CMO Brams' employment: salary set at $165k, quarterly equity grants eliminated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary set at $165,000, representing part-time (50% FTE) basis.","Quarterly equity grants eliminated; annual equity grants remain at Compensation Committee's discretion.","Amendment effective January 1, 2025, approved by Compensation Committee on January 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179838,"accession_number":"0001493152-25-001113","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cingulate completes final FDA-required food effect study for CTx-1301; NDA submission targeted mid-2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed food effect study for CTx-1301 (dexmethylphenidate) in 26 healthy adults using 50mg dose.","No serious adverse events reported; data readout on bioavailability with/without food expected Q2 2025.","Final FDA-required study before NDA submission, which is planned for mid-2025.","2022 study with 25mg dose already showed CTx-1301 can be taken with or without food.","CTx-1301 designed as once-daily stimulant for ADHD covering entire active day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196614,"accession_number":"0001493152-24-051196","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Cingulate raises $5M via 9% promissory note; cash runway into Q4 2025, NDA target mid-2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $5.0M from $5.48M unsecured note (9% interest, 18-month maturity, $450K OID).","Cash runway extended to Q4 2025; NDA submission for CTx-1301 targeted for mid-2025.","Lender Streeterville Capital; monthly redemption cap $550K from July 2025; default triggers 15%/5% balance increases.","Guarantees from subsidiaries Cingulate Therapeutics LLC and Cingulate Works, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196613,"accession_number":"0001493152-24-043915","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.","Cash and equivalents $10M at Sep 30, 2024, up from $52K at Dec 31, 2023.","Working capital $9.8M, an increase of $19.5M from negative $9.6M at year-end 2023.","Raised ~$12.5M in Q3; cash runway extended into Q3 2025.","Commenced final FDA food-effect study for CTx-1301; data readout by end of 2024; NDA submission targeted mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196612,"accession_number":"0001493152-24-041042","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cingulate increases ATM offering capacity by $8.34M to $23.54M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price under ATM raised from $15,196,658 to $23,536,658.","Prospectus supplement filed for additional $8,340,000 of common stock under the Sales Agreement with H.C. Wainwright.","Prior sales of $11,323,947.19 in common stock completed under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196611,"accession_number":"0001493152-24-039645","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cingulate raises $11.7M, extends cash runway through Q2 2025; NDA for CTx-1301 targeted mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised approximately $11.7 million in capital during August and September 2024.","Cash and cash equivalents of approximately $10 million as of September 30, 2024.","Cash runway extended through second quarter of 2025 to fund clinical, manufacturing, and regulatory activities.","NDA filing for CTx-1301 targeting mid-2025 for potential FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196610,"accession_number":"0001493152-24-039532","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cingulate CEO Shane Schaffer charged with aggravated domestic battery; board reaffirms support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Shane Schaffer charged with one count of aggravated domestic battery on September 23, 2024.","Board of Directors expresses full confidence and support for Schaffer to continue leading the company.","No additional details on the charge or its potential effect on management were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212922,"accession_number":"0001493152-24-035960","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Cingulate starts final FDA-required study for lead ADHD asset CTx-1301; raises $10M+","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Commenced final FDA-required food effect study for CTx-1301 (dexmethylphenidate) for ADHD; data readout expected by end of 2024.","Raised over $10M in additional capital since mid-August 2024, including 58% from at-the-market facility.","Received notification from Nasdaq that company is now in compliance with listing requirements.","Reinstated CEO/COO/CFO base salaries to original levels ($503K, $424K, $350K) after late-2023 reductions.","Cost containment measures have saved approximately $1.45M cumulatively; headcount remains ~40% below 2023 levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212921,"accession_number":"0001493152-24-035564","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cingulate regains Nasdaq minimum bid price compliance; panel monitor through May 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Formally notified on September 9, 2024 of regained compliance with $1.00 minimum bid price requirement.","Previously received deficiency notice on June 17, 2024; exception granted through August 23, 2024.","Remains subject to discretionary panel monitor until May 21, 2025 per Nasdaq Rule 5815(d)(4)(A)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212920,"accession_number":"0001493152-24-034734","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cingulate ups ATM offering capacity by $3.87M to $15.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased max aggregate offering price under ATM agreement from $11.33M to $15.20M.","Filed prospectus supplement for additional $3,870,000 of common stock issuance.","Prior sales under the agreement totaled $11,323,947.19 before this increase.","At-market offering continues through H.C. Wainwright & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212919,"accession_number":"0001493152-24-034285","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cingulate reports 2,179,755 shares outstanding as of Aug 28, 2024 after equity sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Aug 28, 2024, common shares outstanding were 2,179,755.","Sales occurred under Jan 2023 At The Market Offering Agreement and Apr 2023 Lincoln Park Capital purchase agreement.","No other material updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212918,"accession_number":"0001493152-24-034148","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cingulate shareholders approve warrant issuance exceeding 20% of outstanding stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on August 28, 2024: 2,277,270 for, 189,572 against, 118,269 abstain.","Approval needed under Nasdaq Listing Rule 5635(d) for warrants from June 28 inducement letter.","Adjournment proposal withdrawn as sufficient votes existed for the issuance proposal.","Warrants issued in connection with H.C. Wainwright engagement letter dated December 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212917,"accession_number":"0001493152-24-032926","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.","Previously sold $8.47M of common stock under the Sales Agreement with H.C. Wainwright & Co.","European patent (EP 3261625) granted for lead asset CTx-1301 (dexmethylphenidate) for ADHD on August 14, 2024.","Patent covers up to 30 European territories, including the United Kingdom."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212916,"accession_number":"0001493152-24-031463","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q2 net loss narrows to $3.2M; FDA clears NDA filing for ADHD drug CTx-1301","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.2M in Q2 2024 vs $6.6M in Q2 2023; R&D expenses fell to $1.9M from $4.5M YoY.","Cash and equivalents $0.4M at June 30; received $1.6M net proceeds from warrant inducement closed July 1.","FDA confirmed remaining clinical requirements; NDA submission for CTx-1301 targeted for first half 2025.","Completed 1-for-12 reverse stock split on Aug 9 to regain compliance with Nasdaq $1.00 bid price rule.","Commissioned payer study (10 payers, 121M lives) found CTx-1301 likely to gain coverage; licensing discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212915,"accession_number":"0001493152-24-030496","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["3.01","3.03","5.03","9.01"],"status":"ready","headline":"Cingulate approves 1-for-12 reverse stock split to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq panel granted bid price exception through Aug 23, 2024, requiring reverse split by Aug 9 and $1 close for 10 days.","Company filed 1-for-12 reverse stock split effective Aug 9, 2024; par value unchanged, authorized shares unchanged.","Reverse split converts every 12 shares into 1; fractional shares rounded up; CUSIP changes to 17248W303.","Stockholders approved reverse split ratio range 1:2 to 1:15 on July 30; Board chose 1:12.","Company had been under discretionary panel monitor through May 2025; delisting notice received June 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212914,"accession_number":"0001493152-24-029624","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cingulate shareholders approve reverse stock split at ratio up to 1:15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved with 3,458,756 votes for, 885,007 against, 28,939 abstain.","Board can set ratio from 1-for-2 to 1-for-15 at any time within one year.","Adjournment proposal also passed (3,469,676 for) but was unnecessary due to sufficient votes.","Special Meeting held July 30, 2024; split intended to maintain Nasdaq listing compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212913,"accession_number":"0001493152-24-025724","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Cingulate announces warrant exercise for $1.86M gross proceeds; new Series C/D warrants issued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Immediate cash exercise of Series A (2.125M shares) and Series B (1.0625M shares) warrants at reduced price $0.585/share (was $2.00).","Gross proceeds ~$1.86M; proceeds for CTx-1301 development, working capital, and general corporate purposes.","Company issues new Series C warrants (4.25M shares) and Series D warrants (2.125M shares) at $0.585/share, exercisable after stockholder approval.","H.C. Wainwright as placement agent; receives 8% cash fee and placement agent warrants for 255,000 shares at $0.7313/share.","Stockholder meeting required within 90 days to approve new warrant exercises per Nasdaq Listing Rule 5635."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52573052.78661088,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-07-01T23:59:59+00:00|212913"}